Lanzol

Lansoprazole, the active ingredient in Lanzol, is a proton pump inhibitor presented as an oral dosage form for oral use. It reduces gastric acid production and is approved for adult patients in the management of gastro‑esophageal reflux disease, peptic ulcer disease, Helicobacter pylori eradication regimens, and Zollinger‑Ellison syndrome.

GNH USA supplies Lanzol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU GMP standards and providing reliable global distribution.

Lanzol (lansoprazole) is used to treat acid‑related disorders by decreasing gastric acid secretion.

- Gastro‑esophageal reflux disease (GERD): alleviates heartburn and esophageal irritation by maintaining a higher gastric pH. - Peptic ulcer disease: promotes ulcer healing and prevents recurrence through sustained acid suppression. - Helicobacter pylori eradication regimens: enhances antibiotic efficacy by creating a less acidic gastric environment. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with gastrin‑producing tumors.

Lanzol may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache - Diarrhea - Nausea - Abdominal pain - Flatulence - Constipation

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis, angioedema) - Clostridioides difficile‑associated diarrhea - Low magnesium levels (hypomagnesemia) - Liver enzyme elevations - Bone fractures with long‑term use

Before initiating therapy, consider the following safety measures.

- Assess renal function: dose adjustment may be needed in severe impairment. - Evaluate for known hypersensitivity: discontinue if allergic reaction occurs. - Monitor long‑term users: consider bone health and magnesium levels. - Use cautiously in patients with liver disease: adjust based on hepatic function. - Store at room temperature: keep in the original container, protect from moisture and light.

Lanzol can interact with several medicines; clinical judgment is required.

Major Interactions (Avoid): - Co‑administration with clarithromycin or ketoconazole: may increase lansoprazole plasma levels. - Use with atazanavir or rilpivirine: reduced antiviral efficacy. - Concomitant use of methotrexate: increased risk of toxicity.

Moderate Interactions (Monitor Closely): - Co‑administration with warfarin: may enhance anticoagulant effect. - Use with digoxin: possible increase in serum digoxin concentrations. - Combination with antiplatelet agents (e.g., clopidogrel): reduced antiplatelet activity.